Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.34B 3.13B 2.86B 5.37B 368B 5.46B 36.88B 14.4B 184B 14.47B 14.16B 614B P/E 2024
15.9x
P/E 2025 13.9x
Enterprise Value 3.15B 2.73B 2.56B 2.33B 4.39B 301B 4.46B 30.12B 11.76B 150B 11.82B 11.56B 502B EV / Sales 2024
4.02x
EV / Sales 2025 3.67x
Free-Float
99.94%
Yield 2024 *
-
Yield 2025 -
1 day+0.03%
1 month+0.06%
3 months+1.12%
6 months+33.43%
Current year+34.92%
1 month 31.48
Extreme 31.48
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.74
Extreme 0.74
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Director/Board Member 48 15/07/2026
Director/Board Member - 15/07/2026
Director/Board Member - 15/07/2026
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Issuer sale

Director

-63,583 0.0519%
15/7/26 Issuer sale

Director

-130,857 0.1069%
15/7/26 Issuer sale

Executive/Senior Manager

-1,051,183 0.8587%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+54.82%+111.63% 3.85B
+1.15%+4.77%+44.05%+0.07% 79.68B
+0.97%+4.90%-0.37%+26.99% 50.61B
-1.22%-2.62%+15.13%+166.74% 48.81B
-0.66%+5.25%-47.97%-48.32% 46.91B
+0.58%+1.95%+55.57%-22.89% 30.86B
-1.41%+16.93%+134.20%-37.02% 25.42B
-0.52%+1.71%+40.24%+84.55% 24.48B
-0.42%+5.37%+8.99%+187.03% 21.2B
-3.16%-1.97%+61.11%+157.26% 16.39B
Average -0.46%+3.02%+36.58%+62.60% 34.82B
Weighted average by Cap. -0.12%+2.87%+27.27%+42.04%

Financials

2024 2025
Net sales 492M 426M 400M 364M 686M 46.93B 696M 4.7B 1.84B 23.49B 1.85B 1.81B 78.37B 589M 511M 479M 436M 821M 56.21B 834M 5.64B 2.2B 28.14B 2.21B 2.16B 93.87B
Net income 164M 142M 133M 121M 228M 15.64B 232M 1.57B 612M 7.83B 615M 602M 26.12B 214M 186M 174M 159M 299M 20.46B 304M 2.05B 801M 10.24B 805M 787M 34.16B
Net Debt -514M -446M -418M -381M -717M -49.09B -729M -4.92B -1.92B -24.57B -1.93B -1.89B -81.97B -706M -612M -574M -523M -985M -67.42B -1B -6.76B -2.64B -33.75B -2.65B -2.59B -113B
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CPRX Stock